Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 10/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | GGPS1 | O95749 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3794088 | 0.98 | FDPS (0.40) | FDPSSMPD1SPHK1GGPS1 | |
| SCHEMBL15573847 | 0.84 | OPRM1 (0.42) | FDPSSMPD1SPHK1GGPS1 | |
| SCHEMBL11792783 | 0.84 | OPRM1 (0.42) | FDPSSMPD1SPHK1GGPS1 | |
| SCHEMBL8071809 | 0.84 | OPRM1 (0.42) | FDPSSMPD1SPHK1GGPS1 | |
| SCHEMBL19253997 | 0.84 | OPRM1 (0.42) | FDPSSMPD1SPHK1GGPS1 | |
| Fluoride SCHEMBL5521472 | 0.76 | FDPS (0.40) | FDPSSMPD1SPHK1GGPS1 | |
| SCHEMBL9508445 | 0.75 | OPRM1 (0.40) | FDPSSMPD1SPHK1 | |
| SCHEMBL9494558 | 0.74 | FAAH (0.44) | SPHK1 | |
| SCHEMBL6558334 | 0.74 | FDPS (0.45) | FDPSSMPD1SPHK1GGPS1 | |
| SCHEMBL21903335 | 0.74 | SPHK1 (0.43) | FDPSSMPD1SPHK1GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1001 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4392003-A1 | PERSONAL CARE COMPOSITIONS | Colgate-Palmolive Company (US) | 2024-07-03 | — | — | EP | claimed |
| US-11998628-B2 | Personal care compositions | COLGATE-PALMOLIVE COMPANY (US) | 2024-06-04 | — | — | US | claimed |
| WO-2023086227-A1 | PERSONAL CARE COMPOSITIONS | COLGATE-PALMOLIVE COMPANY (US) | 2023-05-19 | — | — | WO | claimed |
| US-20230145870-A1 | Personal Care Compositions | COLGATE-PALMOLIVE COMPANY (US) | 2023-05-11 | — | — | US | claimed |
| US-11484503-B2 | Tablet comprising separate binder and erythritol | FERTIN PHARMA A/S (DK) | 2022-11-01 | — | — | US | claimed |
| WO-2021067216-A1 | HAIR TREATMENT COMPOSITION | L'OREAL (FR) | 2021-04-08 | — | — | WO | claimed |
| US-20210093542-A1 | HAIR TREATMENT COMPOSITION | L'OREAL (FR) | 2021-04-01 | — | — | US | claimed |
| WO-2017185147-A1 | NANOSTRUCTURED LIPID CARRIERS AND METHODS FOR MAKING AND USING THEM | L'OREAL (FR) | 2017-11-02 | — | — | WO | claimed |
| WO-2017185155-A1 | NANOSTRUCTURED LIPID CARRIERS AND METHODS FOR MAKING AND USING THEM | L'OREAL (FR) | 2017-11-02 | — | — | WO | claimed |
| US-20140234225-A1 | METHOD OF TREATMENT USING NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-08-21 | — | — | US | claimed |
| US-20040258758-A1 | Nanoparticulate topiramate formulations | ELAN PHARMA INTERNATIONAL, LTD. | 2004-12-23 | — | — | US | claimed |
| EP-1471887-A2 | NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER | Elan Pharma International Limited (IE) | 2004-11-03 | — | — | EP | claimed |
| US-20040208833-A1 | Novel fluticasone formulations | ELAN PHARMA INTERNATIONAL LTD. | 2004-10-21 | — | — | US | claimed |
| WO-2004078162-A1 | NANOPARTICULATE TOPIRAMATE FORMULATIONS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2004-09-16 | — | — | WO | claimed |
| US-20040164194-A1 | System and method for milling materials | ELAN PHARMA INTERNATIONAL LIMITED | 2004-08-26 | — | — | US | claimed |
| WO-2004069225-A1 | NOVEL FLUTICASONE FORMULATIONS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2004-08-19 | — | — | WO | claimed |
| WO-2004050059-A1 | LOW VISCOSITY LIQUID DOSAGE FORMS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2004-06-17 | — | — | WO | claimed |
| US-20040105889-A1 | Low viscosity liquid dosage forms | ELAN PHARMA INTERNATIONAL LIMITED | 2004-06-03 | — | — | US | claimed |
| US-20030185869-A1 | Having lysozyme adsorbed onto or associated with the surface of an active agent | ELAN PHARMA INTERNATIONAL LTD. | 2003-10-02 | — | — | US | claimed |
| WO-2003066021-A2 | DRUG NANOPARTICLES WITH LYSOZYME SURFACE STABILISER | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-08-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093542-A1 | HAIR TREATMENT COMPOSITION | SORD, DPM1, HOGA1 | FDPS 4728/4885SMPD1 372/4885SPHK1 231/4885 |
| US-20040258758-A1 | Nanoparticulate topiramate formulations | FAH, MTHFD1, DHODH | FDPS 229/4885SMPD1 1881/4885SPHK1 996/4885 |
| US-20140234225-A1 | METHOD OF TREATMENT USING NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER | LPO, LCT, LIPA | FDPS 2908/4885SMPD1 75/4885SPHK1 1841/4885 |
| US-20030185869-A1 | Having lysozyme adsorbed onto or associated with the surface of an active agent | LPO, LCT, CTSA | FDPS 3804/4885SMPD1 80/4885SPHK1 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.